INTRODUCTION: We investigated the predictive and prognostic effects of VeriStrat, a serum or plasma-based assay, on response and survival in a subset of patients enrolled on the NCIC Clinical Trials Group, BR.21 phase III trial oferlotinib versus placebo in previously treated advanced non-small-cell lung cancer patients. METHODS: Pretreatment plasma samples were available for 441 of 731 enrolled patients and were provided as anonymized aliquots to Biodesix. The VeriStrat test was performed in a Clinical Laboratory Improvement Act-accredited laboratory at Biodesix, Inc. (Boulder, CO). The results (Good, Poor) were returned to NCIC Clinical Trials Group, which performed all the statistical analyses. RESULTS: VeriStrat testing was successful in 436 samples (98.9%), with 61% classified as Good. VeriStrat was prognostic for overall survival in both erlotinib-treated patients and those on placebo, independent of clinical covariates. For VeriStrat Good patients, the median survival was 10.5 months on erlotinib versus 6.6 months for placebo (hazard ratio 0.63, 95% confidence interval 0.47-0.85, p = 0.002). For VeriStrat Poor patients, the median survival was 4 months for patients receiving erlotinib, and 3.1 months for placebo (hazard ratio: 0.77, 95% confidence interval 0.55-1.06, p = 0.11). VeriStrat was predictive for objective response (p = 0.002), but was not able to predict for differential survival benefit from erlotinib (interaction p = 0.48). Similar results were found for progression-free survival. CONCLUSION: We were able to confirm that VeriStrat is predictive of objective response to erlotinib. VeriStrat is prognostic for both OS and progression-free survival, independent of clinical features, but is not predictive of differential survival benefit versus placebo.
RCT Entities:
INTRODUCTION: We investigated the predictive and prognostic effects of VeriStrat, a serum or plasma-based assay, on response and survival in a subset of patients enrolled on the NCIC Clinical Trials Group, BR.21 phase III trial of erlotinib versus placebo in previously treated advanced non-small-cell lung cancerpatients. METHODS: Pretreatment plasma samples were available for 441 of 731 enrolled patients and were provided as anonymized aliquots to Biodesix. The VeriStrat test was performed in a Clinical Laboratory Improvement Act-accredited laboratory at Biodesix, Inc. (Boulder, CO). The results (Good, Poor) were returned to NCIC Clinical Trials Group, which performed all the statistical analyses. RESULTS: VeriStrat testing was successful in 436 samples (98.9%), with 61% classified as Good. VeriStrat was prognostic for overall survival in both erlotinib-treated patients and those on placebo, independent of clinical covariates. For VeriStrat Good patients, the median survival was 10.5 months on erlotinib versus 6.6 months for placebo (hazard ratio 0.63, 95% confidence interval 0.47-0.85, p = 0.002). For VeriStrat Poor patients, the median survival was 4 months for patients receiving erlotinib, and 3.1 months for placebo (hazard ratio: 0.77, 95% confidence interval 0.55-1.06, p = 0.11). VeriStrat was predictive for objective response (p = 0.002), but was not able to predict for differential survival benefit from erlotinib (interaction p = 0.48). Similar results were found for progression-free survival. CONCLUSION: We were able to confirm that VeriStrat is predictive of objective response to erlotinib. VeriStrat is prognostic for both OS and progression-free survival, independent of clinical features, but is not predictive of differential survival benefit versus placebo.
Authors: Christine H Chung; Erin H Seeley; Heinrich Roder; Julia Grigorieva; Maxim Tsypin; Joanna Roder; Barbara A Burtness; Athanassios Argiris; Arlene A Forastiere; Jill Gilbert; Barbara Murphy; Richard M Caprioli; David P Carbone; Ezra E W Cohen Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-01-19 Impact factor: 4.254
Authors: David P Carbone; J Stuart Salmon; Dean Billheimer; Heidi Chen; Alan Sandler; Heinrich Roder; Joanna Roder; Maxim Tsypin; Roy S Herbst; Anne S Tsao; Hai T Tran; Thao P Dang Journal: Lung Cancer Date: 2009-12-29 Impact factor: 5.705
Authors: Joseph M Amann; Ju-Whei Lee; Heinrich Roder; Julie Brahmer; Adriana Gonzalez; Joan H Schiller; David P Carbone Journal: J Thorac Oncol Date: 2010-02 Impact factor: 15.609
Authors: Jean-Yves Douillard; Frances A Shepherd; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Mei-Lin Liao; Helge Bischoff; Martin Reck; Mark V Sellers; Claire L Watkins; Georgina Speake; Alison A Armour; Edward S Kim Journal: J Clin Oncol Date: 2009-12-28 Impact factor: 44.544
Authors: Juan An; Chuan-Hao Tang; Na Wang; Yi Liu; Jin Lv; Bin Xu; Xiao-Yan Li; Wan-Feng Guo; Hong-Jun Gao; Kun He; Xiao-Qing Liu Journal: Oncol Lett Date: 2018-04-11 Impact factor: 2.967
Authors: Consuelo Buttigliero; Frances A Shepherd; Fabrice Barlesi; Brian Schwartz; Sergey Orlov; Adolfo G Favaretto; Armando Santoro; Vera Hirsh; Rodryg Ramlau; Adele R Blackler; Joanna Roder; David Spigel; Silvia Novello; Wallace Akerley; Giorgio V Scagliotti Journal: Oncologist Date: 2018-08-23
Authors: Mani Keshtgarpour; Wei Seong Tan; Jack Zwanziger; Saria Awadalla; Fredrick G Langi; Arkadiusz Z Dudek Journal: Anticancer Res Date: 2016-04 Impact factor: 2.480